BioStock: FDA grants Abliva’s NV354 Orphan Drug Designation

Biotech Abliva kicked the week off by announcing positive news from the United States. The FDA grants Abliva’s candidate NV354 Orphan Drug Designation, a designation that entails several regulatory advantages for the candidate. BioStock talked to CEO Ellen K. Donnelly about what this means for the development of NV354.

Read the interview with Abliva's CEO Ellen K. Donnelly at biostock.se:

https://www.biostock.se/en/2023/04/fda-grants-ablivas-nv354-orphan-drug-designation/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/